05 November 2024
05 November 2024
Polling by the site FiveThirtyEight on 3 November had current Vice President Kamala Harris with a less than 1% lead over former President Donald Trump.
Increasingly, injectables manufacturers recognise that to achieve maximum profitability, they need to focus on the value they provide.
The approval process for AVT05 is expected to conclude by Q4 2025.
In an end-of-Phase II meeting, the FDA indicated support for accelerated approval based on existing clinical data.
Syndax received $350m upfront in return for a 13.8% royalty on Niktimvo鈥檚 net US sales.
The patents are for salmonella-based approaches to enhance the efficacy of immune checkpoint inhibitors and elicit immune responses.
The company is preparing to launch a Phase Ib/II study in the US and Japan in the first quarter of 2025.
The new structure, resembling a polymer, protects peptides from degradation and facilitates their entry to cells.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
